Firmagon® (Degarelix) — First-in-Class GnRH Antagonist for Prostate Cancer

Immediate Testosterone Suppression Without Testosterone Surge — Critical Advantage Over GnRH Agonists

Firmagon® (Degarelix) is a first-in-class gonadotropin-releasing hormone (GnRH) receptor antagonist used for androgen deprivation therapy (ADT) in men with advanced prostate cancer requiring testosterone suppression. Unlike GnRH agonists such as Zoladex (Goserelin) or Leuprolide — which cause an initial testosterone surge (flare) of 1-2 weeks before achieving suppression — Firmagon immediately and competitively blocks GnRH receptors in the pituitary gland, shutting down LH and FSH production within hours and achieving castration-level testosterone without any flare phenomenon.

This absence of testosterone flare is Firmagon’s most critical clinical advantage — making it the preferred androgen deprivation therapy in patients with symptomatic bone metastases, spinal cord compression, bladder outflow obstruction, or severe urinary symptoms where a testosterone surge could cause life-threatening clinical deterioration.

A.K. Pharma is a trusted medicine distributor in Delhi supplying genuine Firmagon (Degarelix) to hospitals, oncology centres, urology clinics, and pharmacies across India. Manufactured by Ferring Pharmaceuticals, Firmagon represents a significant advance in hormonal therapy for prostate cancer — offering both immediate testosterone suppression and potential cardiovascular advantages over GnRH agonist-based ADT.

What is Firmagon (Degarelix)?

Firmagon contains Degarelix — a synthetic decapeptide GnRH receptor antagonist. Unlike GnRH agonists which initially stimulate GnRH receptors before causing receptor downregulation and desensitisation, Degarelix directly and competitively blocks GnRH receptors in the anterior pituitary — immediately preventing GnRH from stimulating LH and FSH release.

The mechanism difference is clinically fundamental:

GnRH Agonists (Zoladex, Leuprolide):

• Initially stimulate GnRH receptors → LH and FSH surge → testosterone surge (flare) for 1-2 weeks
• Then receptor downregulation → testosterone falls to castration levels
• Antiandrogen cover (Bicalutamide) required for 4 weeks to mitigate flare
• Testosterone levels may fluctuate with each injection

Firmagon (GnRH Antagonist):

• Immediately blocks GnRH receptors competitively → no LH/FSH surge → no testosterone surge
• Testosterone falls to castration levels within 3 days — 97% of patients
• No antiandrogen cover required
• Stable, sustained testosterone suppression throughout monthly dosing

Full prescribing information is available at the FDA label for Degarelix.

Clinical Studies and Evidence

CS21 Trial (Degarelix vs Leuprolide in Prostate Cancer) Published in the Journal of Urology (2009), the pivotal CS21 trial — a Phase 3 randomised controlled trial involving 610 patients — compared Degarelix to Leuprolide (GnRH agonist) in patients with prostate cancer requiring ADT. Key findings:

• Degarelix achieved testosterone suppression to castration levels (≤50 ng/dL) in 97% of patients within 3 days — significantly faster than Leuprolide
• No testosterone surge was observed with Degarelix — while 80% of Leuprolide patients experienced testosterone flare
• PSA declined significantly faster with Degarelix in the first month — 64% reduction at day 14 vs 18% with Leuprolide
• Both achieved comparable sustained testosterone suppression by day 28 and beyond

CS21A Extension Study (Long-Term Degarelix Data) The CS21A extension study demonstrated sustained testosterone suppression and PSA control with continuous monthly Degarelix injections over 5 years — with a consistent safety profile supporting long-term use. PSA progression-free survival was maintained in a significant proportion of patients receiving continuous Degarelix.

Cardiovascular Safety — Meta-Analysis Evidence A landmark meta-analysis published in the European Heart Journal (2015) — pooling data from 6 randomised trials — demonstrated that Degarelix was associated with significantly fewer major adverse cardiovascular events (MACE) compared to GnRH agonists in patients with pre-existing cardiovascular disease. The hazard ratio for MACE was 0.44 (95% CI 0.26-0.74) favouring Degarelix. This cardiovascular advantage may be related to the avoidance of testosterone flare and the distinct hormonal profile with Degarelix.

PRONOUNCE Trial (Degarelix vs Leuprolide — Cardiovascular Outcomes) The PRONOUNCE trial — specifically designed to evaluate cardiovascular outcomes — compared Degarelix and Leuprolide in prostate cancer patients with pre-existing cardiovascular disease. While the trial was underpowered to show statistical significance, numerical trends supported fewer cardiovascular events with Degarelix — particularly in patients with established CVD — consistent with prior meta-analysis data.

RADICAL-PC Registry Data Real-world registry data from the RADICAL-PC programme confirmed Degarelix’s efficacy and tolerability in routine clinical practice — with consistent testosterone suppression and PSA control observed across diverse patient populations.

Available Strengths

Firmagon is available in the following strengths:

Each vial contains lyophilised Degarelix powder — reconstituted with sterile water for injection immediately before subcutaneous administration into the abdominal region.

Important: The starting dose of Firmagon is 240mg — administered as two separate 120mg injections at two different abdominal sites simultaneously on day 1. Thereafter monthly 80mg maintenance doses are given as a single injection. This loading dose regimen ensures rapid achievement of castration-level testosterone from day 1.

Indications — What Firmagon is Used For

Primary Indication:

• Advanced hormone-sensitive prostate cancer (HSPC) requiring androgen deprivation therapy
• Locally advanced, node-positive, or metastatic prostate cancer

Specific Clinical Situations Where Firmagon is Strongly Preferred Over GnRH Agonists:

• Symptomatic bone metastases — testosterone flare could cause severe bone pain or pathological fractures
• Spinal cord compression or high risk of spinal cord compression — testosterone flare could precipitate acute neurological deterioration
• Bladder outflow obstruction or severe LUTS — testosterone flare could cause acute urinary retention
• Ureteral obstruction — testosterone flare could worsen obstruction
• Established cardiovascular disease — potential cardiovascular safety advantage
• Need for rapid testosterone suppression before starting radiotherapy
• Patients where antiandrogen cover (required with GnRH agonists) is contraindicated or undesirable

For detailed indication information refer to MedlinePlus Degarelix.

Key Benefits of Firmagon

No Testosterone Surge — The Most Important Advantage Firmagon’s most critical clinical benefit is the complete absence of testosterone flare — avoiding the potentially life-threatening clinical deterioration that can occur with GnRH agonist-induced testosterone surge in patients with bone metastases, spinal cord compression, or urinary obstruction. This makes Firmagon the standard of care for symptomatic advanced prostate cancer where flare cannot be tolerated.

Rapid Castration in 3 Days 97% of patients achieve castration-level testosterone (≤50 ng/dL) within 3 days of starting Firmagon — compared to 2-4 weeks with GnRH agonists. This rapid suppression is clinically valuable in patients who need urgent testosterone reduction.

Faster PSA Response Firmagon achieves significantly faster PSA reduction than GnRH agonists in the first month — with 64% PSA reduction by day 14 vs 18% with Leuprolide in the CS21 trial. Faster PSA response reflects more rapid androgen deprivation and may translate to faster symptom relief.

No Need for Antiandrogen Cover Unlike GnRH agonists which require 4 weeks of antiandrogen therapy (e.g. Bicalutamide) to cover the testosterone flare, Firmagon requires no antiandrogen cover — simplifying treatment, reducing polypharmacy, and avoiding antiandrogen side effects.

Stable Consistent Testosterone Suppression Firmagon maintains consistently low testosterone levels throughout the monthly dosing interval — without the testosterone escape or fluctuations that can occasionally occur with GnRH agonist implants.

Potential Cardiovascular Advantage Meta-analysis data suggests fewer MACE events with Degarelix vs GnRH agonists in patients with pre-existing cardiovascular disease — a clinically important consideration given the high cardiovascular risk in the prostate cancer population.

No Histamine Release Unlike some GnRH antagonists, Degarelix was specifically designed to minimise histamine-mediated reactions — making injection site reactions the main local side effect rather than systemic allergic reactions.

How Firmagon Works

The hypothalamic-pituitary-gonadal (HPG) axis controls testosterone production:

• Hypothalamus releases GnRH in pulses → stimulates pituitary GnRH receptors
• Pituitary releases LH and FSH → LH stimulates Leydig cells in testes → testosterone production
• Testosterone feeds back to hypothalamus and pituitary — reducing GnRH, LH, FSH release

Firmagon works by:

Step 1 — Immediate GnRH Receptor Blockade: Degarelix binds competitively to GnRH receptors in the anterior pituitary with high affinity — directly blocking GnRH from binding. This is immediate and complete — unlike GnRH agonists which first stimulate these receptors before desensitising them.

Step 2 — Immediate LH and FSH Suppression: Without GnRH receptor activation, LH and FSH secretion drops rapidly — within hours of Degarelix administration. There is no initial LH/FSH surge.

Step 3 — Testosterone Falls to Castration Levels: Without LH stimulation, testicular Leydig cells stop producing testosterone — plasma testosterone falls to castration levels (≤50 ng/dL) within 3 days in 97% of patients.

Step 4 — Sustained Suppression with Monthly Dosing: Monthly 80mg maintenance injections maintain GnRH receptor blockade — sustaining castration-level testosterone suppression continuously without the fluctuations associated with GnRH agonist depot implants.

For a detailed mechanism overview refer to the European Association of Urology (EAU) Prostate Cancer Guidelines and American Urological Association (AUA) Advanced Prostate Cancer Guidelines.

Firmagon vs Zoladex — Key Comparison

Dosage and Administration

Starting Dose (Day 1 only):

• 240mg subcutaneously — administered as two separate 120mg injections at two different abdominal sites simultaneously
• Each 120mg dose is reconstituted in 3mL sterile water for injection → administered as deep SC injection

Maintenance Dose (Monthly thereafter):

• 80mg subcutaneously once every 28 days
• Reconstitute in 4.2mL sterile water for injection → administer as deep SC injection
• Administer in the abdominal region — rotating sites with each injection
• Avoid areas where pressure may be exerted (waistband, belt, near ribs)

Administration Technique:

• Reconstitute lyophilised powder with provided sterile water — swirl gently, do not shake
• Allow to dissolve completely — approximately 15 minutes at room temperature
• Draw up reconstituted solution — tilt vial to avoid foam
• Inject subcutaneously into abdominal fat — not intramuscularly or intravenously
• Use a 23-gauge 1.5-inch needle — ensure needle is in SC tissue
• Apply gentle pressure after injection — do not rub the injection site

Monitoring:

• Testosterone levels at baseline, month 1, and periodically
• PSA levels every 3 months
• Bone density — DEXA scan at baseline and annually (ADT causes bone loss)
• Cardiovascular risk factors assessment

Full dosing guidelines available at Drugs.com Degarelix Dosage.

Combination Therapy — Firmagon With Other Prostate Cancer Medicines

In metastatic hormone-sensitive prostate cancer (mHSPC) Firmagon is increasingly used as the ADT backbone in combination with:

• Abirapro (Abiraterone) + Prednisone — LATITUDE trial — for high-risk mHSPC
• Glenza 160mg (Enzalutamide) — ARCHES/ENZAMET trials — for mHSPC
• Docetaxel chemotherapy — for high-volume mHSPC

In castration-resistant prostate cancer (mCRPC) patients initially started on Firmagon are continued on ADT while adding:

• Abirapro (Abiraterone) — for mCRPC
• Glenza 160mg (Enzalutamide) — for mCRPC
• Pivikto (Lutetium-177 PSMA) — for PSMA-positive mCRPC post-AR pathway inhibitor

Who Should Use Firmagon

Firmagon is prescribed for:

• Men with locally advanced, node-positive, or metastatic prostate cancer requiring ADT
• Patients with symptomatic bone metastases — testosterone flare prevention is critical
• Patients with spinal cord compression or high risk of spinal cord compression
• Patients with bladder outflow obstruction or severe LUTS
• Patients with established cardiovascular disease — potential CV safety advantage
• Patients requiring rapid testosterone suppression before radiotherapy
• Patients where GnRH agonist antiandrogen cover is contraindicated

Firmagon is prescribed by urologists, oncologists, and radiation oncologists. A.K. Pharma supplies Firmagon to hospitals, oncology centres, urology clinics, and pharmacies across Delhi and India.

Possible Side Effects

Common side effects: Injection site reactions are the most common side effect — occurring in approximately 40% of patients — including pain (28%), erythema (17%), swelling (6%), induration, and nodule formation. These are typically mild to moderate and transient — lasting days to weeks. They are less severe with maintenance 80mg doses than with the 240mg starting dose. Rotating injection sites and proper subcutaneous technique minimise reactions.

Systemic side effects related to testosterone suppression (shared with all ADT) include hot flushes (26%), weight gain, fatigue, decreased libido, erectile dysfunction, and gynaecomastia.

Serious side effects:

• QT/QTc prolongation — ADT-related effect; monitor ECG in patients with risk factors
• Osteoporosis and fracture risk — long-term ADT causes bone mineral density loss; consider bone-protective therapy (Denosumab, bisphosphonate)
• Metabolic syndrome — ADT increases risk of diabetes, dyslipidaemia, cardiovascular events
• Anaemia — testosterone suppression reduces erythropoiesis
• Depression and cognitive effects — monitor for mood changes

Full side effect information available at FDA Degarelix Safety Information.

Precautions

• Monitor bone mineral density — start bone-protective therapy early in long-term ADT
• Monitor metabolic parameters — fasting glucose, HbA1c, lipid profile
• Monitor cardiovascular risk factors throughout treatment
• QT prolongation — avoid concomitant QT-prolonging medicines; monitor ECG in high-risk patients
• Hypersensitivity — rare cases of anaphylaxis reported; observe patients after first injection
• Hepatic impairment — use with caution in severe hepatic impairment
• Glucose control — ADT may worsen glycaemic control in diabetic patients
• Refer to EAU Prostate Cancer Guidelines for complete management context

Storage and Handling

• Store at room temperature below 30°C
• Keep in original packaging — protect from light and moisture
• Do not refrigerate or freeze
• Reconstituted solution should be administered immediately after preparation — do not store reconstituted solution
• Keep out of reach of children

As a responsible medicine distributor in Delhi, A.K. Pharma stores all oncology medicines including Firmagon under manufacturer-recommended conditions ensuring product integrity for every supply to oncology centres and urology clinics.

Manufacturer Information

Firmagon (Degarelix) is manufactured by Ferring Pharmaceuticals, a privately held global biopharmaceutical company with a significant focus on urology and oncology. Degarelix received FDA approval in December 2008 for advanced prostate cancer — the first GnRH antagonist approved for this indication. A.K. Pharma supplies only genuine Firmagon sourced from authorized Ferring distributors.

Related Prostate Cancer and Oncology Medicines Available at A.K. Pharma

• Zoladex (Goserelin) — GnRH agonist ADT — monthly and 3-monthly implant
• Abirapro (Abiraterone) — CYP17 inhibitor for mCRPC and high-risk mHSPC
• Glenza 160mg (Enzalutamide) — androgen receptor inhibitor for mCRPC and mHSPC
• Pivikto (Lutetium-177) — PSMA-targeted radioligand therapy for mCRPC
• Browse all Cancer Medicines available at A.K. Pharma

Frequently Asked Questions

Q. What is Firmagon used for? Firmagon (Degarelix) is used for androgen deprivation therapy in men with advanced prostate cancer requiring testosterone suppression. It is a GnRH receptor antagonist that immediately suppresses testosterone without the testosterone surge seen with GnRH agonists. More information available at MedlinePlus.

Q. What is the generic name of Firmagon? The generic name of Firmagon is Degarelix. It is a synthetic decapeptide GnRH receptor antagonist — the first in its class approved for prostate cancer.

Q. How is Firmagon different from Zoladex? Firmagon is a GnRH receptor antagonist while Zoladex is a GnRH receptor agonist. The key difference is that Firmagon immediately blocks testosterone production without any initial testosterone surge — while Zoladex causes a 1-2 week testosterone flare before achieving suppression. This makes Firmagon the preferred choice in patients with symptomatic metastases or urinary obstruction where testosterone flare could cause serious harm.

Q. Does Firmagon need antiandrogen cover like Zoladex? No — Firmagon does not require antiandrogen cover (Bicalutamide) because there is no testosterone flare. This simplifies treatment and eliminates antiandrogen-related side effects and costs.

Q. How quickly does Firmagon work? Firmagon achieves castration-level testosterone (≤50 ng/dL) in 97% of patients within 3 days — significantly faster than GnRH agonists which take 2-4 weeks. PSA reduction is also significantly faster — 64% PSA reduction by day 14 compared to 18% with Leuprolide.

Q. Is Firmagon better for patients with heart disease? Meta-analysis data suggests Degarelix is associated with significantly fewer major adverse cardiovascular events compared to GnRH agonists in patients with pre-existing cardiovascular disease — making Firmagon a preferred ADT option in this population according to evolving guideline recommendations.

Q. Is Firmagon available in India? Firmagon can be supplied to hospitals, oncology centres, and pharmacies across India through licensed pharmaceutical distributors. Contact A.K. Pharma — medicine distributor in Delhi — for availability and pricing.

Q. What is the price of Firmagon in India? Firmagon price in India varies by strength and pack size. Contact A.K. Pharma at 011 4172 6999 or WhatsApp +91 9810034827 for current pricing and bulk supply rates.

Q. How to order Firmagon from A.K. Pharma? You can request a quote directly from this page, call us at 011 4172 6999, or WhatsApp us at +91 9810034827 with your requirements and we will respond promptly.

Q. Does A.K. Pharma supply Firmagon in bulk? Yes. A.K. Pharma supplies Firmagon in bulk to oncology centres, urology clinics, hospitals, and pharmacies across Delhi and India. Contact us for bulk pricing and availability.

Why Order Firmagon from A.K. Pharma?

• Licensed medicine distributor in Delhi with all required drug licenses
• 100% genuine Firmagon sourced from authorized Ferring distributors
• Reliable supply to oncology centres and urology clinics across India
• Both 80mg and 120mg presentations available
• Bulk supply available for hospitals and cancer treatment centres
• Prompt response to all quote requests
• Serving urologists and oncologists across Delhi NCR and India

Contact A.K. Pharma for Firmagon Supply 📍 E-2/257A, 2nd Floor, Shastri Nagar, New Delhi 110052 📞 011 4172 6999 📱 WhatsApp: +91 9810034827 🌐 akpharma.in